Re-Directing an Alkylating Agent to Mitochondria Alters Drug Target and Cell Death Mechanism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Mourtada, Rida ^a   Fonseca, Sonali B ^a   Wisnovsky, Simon P ^b   Pereira, Mark P ^b   Wang, Xiaoming ^c   Hurren, Rose ^c   Parfitt, Jeremy ^d   Larsen, Lesley ^e   Smith, Robin A J ^e   Murphy, Michael P ^f   Schimmer, Aaron D ^c   Kelley, Shana O ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CHLORAMBUCIL TRIPHENYLPHOSPHONIUM CONJUGATE; MITOCHONDRIA PENETRATING PEPTIDE CHLORAMBUCIL CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL-PENETRATING PEPTIDES; CHLORAMBUCIL; CROSS-LINKING REAGENTS; DNA, MITOCHONDRIAL; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; LEUKEMIA; MICE; MICE, INBRED NOD; MICE, SCID; MITOCHONDRIA; NECROSIS; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA;

EID: 84876056671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060253     Document Type: Article

References (34)

1. Krumbhaar EB, Krumbhaar HD (1919) The Blood and Bone Marrow in Yelloe Cross Gas (Mustard Gas) Poisoning: Changes produced in the Bone Marrow of Fatal Cases. J Med Res 40: 497-508 493.
2. Gilman A, (1963) The initial clinical trial of nitrogen mustard. Am J Surg 105: 574-578.
3. Anslow WP Jr, Karnofsky DA, Jager V, Smith HW, (1948) The intravenous, subcutaneous and cutaneous toxicity of bis (beta-chloroethyl) sulfide (mustard gas) and of various derivatives. J Pharmacol Exp Ther 93: 1-9.
4. Neidle S, Thurston DE, (2005) Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5: 285-296.
5. Brookes P, Lawley PD, (1961) The reaction of mono- and di-functional alkylating agents with nucleic acids. Biochem J 80: 496-503.
6. Masta A, Gray PJ, Phillips DR, (1995) Nitrogen mustard inhibits transcription and translation in a cell free system. Nucleic Acids Res 23: 3508-3515.
7. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, et al. (1993) G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 268: 8298-8308.
8. Montserrat E, Rozman C, (1993) Chronic lymphocytic leukaemia treatment. Blood Rev 7: 164-175.
9. Begleiter A, Mowat M, Israels LG, Johnston JB, (1996) Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 23: 187-201.
10. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757.
11. Fonseca SB, Pereira MP, Mourtada R, Gronda M, Horton KL, et al. (2011) Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chem Biol 18: 445-453.
12. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO, (2008) Mitochondria-penetrating peptides. Chem Biol 15: 375-382.
13. Yousif L, Stewart KM, Horton KL, Kelley SO, (2009) Mitochondria-penetrating peptides: seqeunce effects and model cargo transport. ChemBioChem 10: 2081-2088.
14. Carreon JR, Stewart KM, Mahon KP Jr, Shin S, Kelley SO, (2007) Cyanine dye conjugates as probes for live cell imaging. Bioorg Med Chem Lett 17: 5182-5185.
15. King MP, Attardi G, (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500-503.
16. Wang C, Curtis JE, Minden MD, McCulloch EA, (1989) Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3: 264-269.
17. Santos JH, Meyer JN, Mandavilli BS, Van Houten B, (2006) Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. Methods Mol Biol 314: 183-199.
18. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, et al. (2006) Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98: 1634-1646.
19. Druzhyna NM, Wilson GL, LeDoux SP, (2008) Mitochondrial DNA repair in aging and disease. Mech Ageing Dev 129: 383-390.
20. Tann AW, Boldogh I, Meiss G, Qian W, Van Houten B, et al. (2011) Apoptosis induced by persistent single-strand breaks in mitochondrial genome: critical role of EXOG (5′-EXO/endonuclease) in their repair. J Biol Chem 286: 31975-31983.
21. Samudio I, Fiegl M, Andreeff M, (2009) Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69: 2163-2166.
22. Fulda S, Galluzzi L, Kroemer G, (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464.
23. Smith RA, Hartley RC, Murphy MP (2011) Mitochondria-Targeted Small Molecule Therapeutics and Probes. Antioxid Redox Signal.
24. King D, Pringle JH, Hutchinson M, Cohen GM, (1998) Processing/activation of caspases,-3 and-7 and-8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia 12: 1553-1560.
25. Tait SW, Green DR, (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621-632.
26. Guidicelli G, Chaigne-Delalande B, Dilhuydy MS, Pinson B, Mahfouf W, et al. (2009) The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. PLoS One 4: e5493.
27. Naito M, Hashimoto C, Masui S, Tsuruo T, (2004) Caspase-independent necrotic cell death induced by a radiosensitizer, 8-nitrocaffeine. Cancer Sci 95: 361-366.
28. Hu X, Xuan Y, (2008) Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 259: 127-137.
29. Ross WCJ (1962) Biological alkylating agents. London: Butterworth & Co. Ltd.
30. Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, et al. (2007) Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 18: 1325-1331.
31. Ganguly S, Chaubey B, Tripathi S, Upadhyay A, Neti PV, et al. (2008) Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 18: 277-286.
32. Alberts DS, Chang SY, Chen HS, Larcom BJ, Jones SE, (1979) Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat Rev 6Suppl: 9-17.
33. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, et al. (2012) Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer Journal 2: e64.
34. Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, et al. (1996) Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38: 335-342.